• PhagoMed

PhagoMed’s PM-477 named as an MIT SOLVE finalist solution



MIT SOLVE, the worlds premier social impact competition, selected PhagoMed’s drug candidate PM-477 as a finalist in the 2020 global competition. PM-477 will compete together with 14 other solutions for up to $100,000 in prize money and the chance to be named an MIT SOLVER team in the MIT SOLVE Global Competition Finals on September 29th, 2020. PM-477 is PhagoMed’s lead drug candidate that targets the #1 vaginal infection, Bacterial Vaginosis (BV). Bacterial Vaginosis affects around 400 million women every year and has dramatic health consequences including pre-term birth, high risk of STD contraction and low quality of life. PM-477 is a precision drug that works by binding to and killing the bacteria that cause Bacterial Vaginosis. At the same time PM-477 cannot bind to the beneficial bacteria in the vaginal microbiome and is therefore a highly precise therapy.

MIT SOLVE selected PM-477 as a finalist due to the high medical need in Bacterial Vaginosis in low-income communities. For more information on PM-477 and the SOLVE competition, please visit the following link. About MIT SOLVE: Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu.

PhagoMed Biopharma GmbH

Leberstraße 20

1110 Vienna

Austria

contact@phagomed.com

Imprint & Privacy Policy